Document is current

Article History

Received: 13 July 2022

Accepted: 24 July 2022

First Online: 1 August 2022

Declarations

:

: All authors have nothing to disclose.

: This study was approved by the ethics review board of the Jikei University School of Medicine [34–056 (11201)] and conducted according to the Declaration of Helsinki.

: Dapagliflozin is approved by the Ministry of Health, Labour and Welfare in Japan and can be used in daily clinical practice, regardless of the CKD stage. Since this was a retrospective observational study, informed consent from the subjects was not required. In addition, the need for written informed consent has been waived in accordance with the Institutional Review Board of the Jikei University School of Medicine and the “Ethical Guidelines for Research on Medicine and Medical Technology Involving Human Subjects”.